Avadel Pharmaceuticals (AVDL) Net Cash Flow (2016 - 2022)
Historic Net Cash Flow for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2022 value amounting to $14.1 million.
- Avadel Pharmaceuticals' Net Cash Flow rose 29664.63% to $14.1 million in Q4 2022 from the same period last year, while for Dec 2022 it was $23.9 million, marking a year-over-year increase of 21898.3%. This contributed to the annual value of $20.8 million for FY2024, which is 14817.07% up from last year.
- According to the latest figures from Q4 2022, Avadel Pharmaceuticals' Net Cash Flow is $14.1 million, which was up 29664.63% from $6.4 million recorded in Q3 2022.
- Avadel Pharmaceuticals' Net Cash Flow's 5-year high stood at $63.8 million during Q1 2020, with a 5-year trough of -$28.2 million in Q2 2018.
- For the 5-year period, Avadel Pharmaceuticals' Net Cash Flow averaged around $2.9 million, with its median value being -$1.4 million (2019).
- The largest annual percentage gain for Avadel Pharmaceuticals' Net Cash Flow in the last 5 years was 2301594.2% (2020), contrasted with its biggest fall of 35976.9% (2020).
- Avadel Pharmaceuticals' Net Cash Flow (Quarter) stood at -$8.4 million in 2018, then soared by 62.79% to -$3.1 million in 2019, then plummeted by 274.55% to -$11.7 million in 2020, then skyrocketed by 38.59% to -$7.2 million in 2021, then surged by 296.65% to $14.1 million in 2022.
- Its Net Cash Flow was $14.1 million in Q4 2022, compared to $6.4 million in Q3 2022 and -$6.8 million in Q2 2022.